DK3354661T3 - Fuldstændigt humant antistof mod human CD137 og anvendelse deraf - Google Patents
Fuldstændigt humant antistof mod human CD137 og anvendelse deraf Download PDFInfo
- Publication number
- DK3354661T3 DK3354661T3 DK15904340.5T DK15904340T DK3354661T3 DK 3354661 T3 DK3354661 T3 DK 3354661T3 DK 15904340 T DK15904340 T DK 15904340T DK 3354661 T3 DK3354661 T3 DK 3354661T3
- Authority
- DK
- Denmark
- Prior art keywords
- human
- completely
- antibody
- human antibody
- completely human
- Prior art date
Links
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 title 1
- 102000050327 human TNFRSF9 Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2015/090226 WO2017049452A1 (zh) | 2015-09-22 | 2015-09-22 | 抗人cd137的完全人抗体及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3354661T3 true DK3354661T3 (da) | 2020-07-06 |
Family
ID=58385511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15904340.5T DK3354661T3 (da) | 2015-09-22 | 2015-09-22 | Fuldstændigt humant antistof mod human CD137 og anvendelse deraf |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10875926B2 (da) |
| EP (1) | EP3354661B1 (da) |
| JP (1) | JP6845846B6 (da) |
| CN (2) | CN108026169B (da) |
| DK (1) | DK3354661T3 (da) |
| ES (1) | ES2802994T3 (da) |
| HR (1) | HRP20201022T1 (da) |
| WO (1) | WO2017049452A1 (da) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11214618B2 (en) | 2016-06-20 | 2022-01-04 | F-Star Therapeutics Limited | LAG-3 binding members |
| UA128304C2 (uk) | 2016-07-14 | 2024-06-05 | Ґенмаб А/С | Мультиспецифічне антитіло до cd40 і cd137 |
| BR112019017241A2 (pt) | 2017-04-13 | 2020-04-14 | Agenus Inc | anticorpos anti-cd137 e métodos de uso dos mesmos |
| WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | Anti-cd137 molecules and use thereof |
| TWI701259B (zh) * | 2017-11-09 | 2020-08-11 | 大陸商上海懷越生物科技有限公司 | ４﹘１ｂｂ抗體及其製備方法和應用 |
| WO2019104716A1 (en) * | 2017-12-01 | 2019-06-06 | Adagene Inc. | Methods for using cd137 ligand as biomarker for treatment with anti-cd137 antibody |
| EP3744734A1 (en) * | 2018-01-22 | 2020-12-02 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-4-1bb antibody, antigen-binding fragment thereof and medical use thereof |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| CA3106048A1 (en) | 2018-07-12 | 2020-01-16 | F-Star Beta Limited | Antibody molecules that bind cd137 and ox40 |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| CN112423845B (zh) | 2018-07-12 | 2024-07-30 | F-星治疗有限公司 | 结合pd-l1和cd137的抗体分子 |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| AU2019312200B2 (en) | 2018-07-23 | 2024-11-14 | Heidelberg Pharma Research Gmbh | Use of anti-CD137 antibody drug conjugate (ADC) in allogeneic cell therapy |
| WO2020077635A1 (zh) * | 2018-10-19 | 2020-04-23 | 苏州丁孚靶点生物技术有限公司 | 抗cd137抗体及其应用 |
| BR112021010402A2 (pt) | 2018-11-30 | 2021-08-24 | Abl Bio Inc. | Anticorpos biespecíficos anti-pd-l1/anti-4-1bb e uso dos mesmos |
| CN113382752B (zh) * | 2019-01-02 | 2025-03-04 | Qlsf生物治疗药物公司 | Cd137激动剂抗体及其用途 |
| US20220111047A1 (en) * | 2019-01-16 | 2022-04-14 | Compass Therapeutics Llc | Formulations of antibodies that bind human cd137 and uses thereof |
| WO2020216947A1 (en) | 2019-04-24 | 2020-10-29 | Heidelberg Pharma Research Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
| CN112010974B (zh) * | 2019-05-30 | 2022-08-09 | 山东博安生物技术股份有限公司 | 一种特异性结合人4-1bb的抗体及其应用 |
| CN112300277A (zh) * | 2019-07-25 | 2021-02-02 | 苏州丁孚靶点生物技术有限公司 | Csf1r抗体、基因、载体、宿主细胞和csf1r拮抗剂 |
| CN112279914A (zh) * | 2019-07-25 | 2021-01-29 | 苏州丁孚靶点生物技术有限公司 | Il4ra抗体、基因、载体、宿主细胞和il4ra拮抗剂 |
| CN112279915A (zh) * | 2019-07-25 | 2021-01-29 | 苏州丁孚靶点生物技术有限公司 | Icos抗体、基因、载体、宿主细胞和icos拮抗剂 |
| CN112794904B (zh) * | 2019-11-13 | 2022-09-30 | 合肥瀚科迈博生物技术有限公司 | 一种抗4-1bb的人源化抗体的用途 |
| CN112794905B (zh) * | 2019-11-13 | 2022-10-04 | 合肥瀚科迈博生物技术有限公司 | 一种能够与人4-1bb结合的分子 |
| CN113004416B (zh) * | 2019-12-19 | 2022-10-04 | 合肥瀚科迈博生物技术有限公司 | 靶向her2-cd137双特异性抗体的构建及其应用 |
| CN113004415B (zh) * | 2019-12-19 | 2022-09-30 | 合肥瀚科迈博生物技术有限公司 | 靶向her2和4-1bb的双特异性抗体及其应用 |
| WO2021209017A1 (zh) * | 2020-04-17 | 2021-10-21 | 苏州丁孚靶点生物技术有限公司 | 一种特异性结合cd137的制剂及其用途 |
| US20230242658A1 (en) * | 2020-06-30 | 2023-08-03 | Nona Biosciences (Suzhou) Co., Ltd. | 4-1bb-binding protein and use thereof |
| WO2024109678A1 (en) * | 2022-11-21 | 2024-05-30 | Beigene, Ltd. | Anti-cd137 antibodies and methods of use |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20000034847A (ko) * | 1998-11-17 | 2000-06-26 | 성재갑 | 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물 |
| US20030118588A1 (en) * | 1999-05-22 | 2003-06-26 | Linda Diehl | Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40 |
| US6887673B2 (en) * | 2002-07-30 | 2005-05-03 | Bristol-Myers Squibb Company | Humanized antibodies against human 4-1BB |
| AR046094A1 (es) | 2003-10-10 | 2005-11-23 | Bristol Myers Squibb Co | Anticuerpos completamente humanos contra 4-1bb humano |
| US7288638B2 (en) * | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| US20070253961A1 (en) * | 2004-06-09 | 2007-11-01 | Ulsan Industrial Education Foundation | Pharmaceutical Composition Comprising the Anti-4-1Bb Antibody for Treating or Preventing Rheumatoid Arthritis |
| EP1851244A4 (en) | 2005-02-15 | 2009-04-15 | Gtc Biotherapeutics Inc | ANTI-CD137 ANTIBODY AS A MEANS FOR THE TREATMENT OF CANCER, AND GLYCOSYLATION VARIANTS THEREOF |
| MX337040B (es) * | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
-
2015
- 2015-09-22 CN CN201580083093.1A patent/CN108026169B/zh active Active
- 2015-09-22 EP EP15904340.5A patent/EP3354661B1/en active Active
- 2015-09-22 US US15/761,992 patent/US10875926B2/en active Active
- 2015-09-22 DK DK15904340.5T patent/DK3354661T3/da active
- 2015-09-22 ES ES15904340T patent/ES2802994T3/es active Active
- 2015-09-22 WO PCT/CN2015/090226 patent/WO2017049452A1/zh not_active Ceased
- 2015-09-22 JP JP2018514891A patent/JP6845846B6/ja active Active
- 2015-09-22 HR HRP20201022TT patent/HRP20201022T1/hr unknown
- 2015-09-22 CN CN202110511953.4A patent/CN113214398B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20201022T1 (hr) | 2020-10-16 |
| CN108026169A (zh) | 2018-05-11 |
| JP2018527939A (ja) | 2018-09-27 |
| WO2017049452A1 (zh) | 2017-03-30 |
| EP3354661B1 (en) | 2020-06-03 |
| CN108026169B (zh) | 2021-05-28 |
| EP3354661A1 (en) | 2018-08-01 |
| CN113214398B (zh) | 2022-04-08 |
| EP3354661A4 (en) | 2019-04-03 |
| JP6845846B6 (ja) | 2021-04-21 |
| US20180282422A1 (en) | 2018-10-04 |
| US10875926B2 (en) | 2020-12-29 |
| CN113214398A (zh) | 2021-08-06 |
| ES2802994T3 (es) | 2021-01-22 |
| JP6845846B2 (ja) | 2021-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3354661T3 (da) | Fuldstændigt humant antistof mod human CD137 og anvendelse deraf | |
| IL269642A (en) | Methods and compositions for enhancing health | |
| DK3221363T3 (da) | Antistoffer mod cd73 og anvendelser deraf | |
| DK3283106T3 (da) | Terapeutiske antistoffer og anvendelser deraf | |
| DK3235830T3 (da) | Interleukin-15-proteinkompleks og anvendelse deraf | |
| DK3099172T3 (da) | Modificeret biologisk bekæmpelsesmiddel og anvendelser deraf | |
| DK3653221T5 (da) | Anti-pvrig-antistoffer og anvendelsesfremgangsmåder | |
| DK3271389T3 (da) | Neutraliserende antistoffer mod gp120 og anvendelse deraf | |
| IL258666A (en) | Natural killer cells and ilc3 cells and uses thereof | |
| DK3333191T3 (da) | Anti-C10ORF54-antistoffer og anvendelser deraf | |
| DK3353210T3 (da) | Anti-TIGIT-antistoffer og fremgangsmåder til anvendelse | |
| DK3357513T3 (da) | Farmaceutisk sammensætning og anvendelse deraf | |
| DK3126388T3 (da) | Anti-EGFRvIII-antistoffer og anvendelser deraf | |
| DK3015526T3 (da) | Hydrofluorolefinbaseret sammensætning og anvendelse deraf | |
| DK3757206T3 (da) | Transduktionsfremgangsmåde og cellebehandling | |
| DK3215532T3 (da) | Anti-TIM3-antistoffer og fremgangsmåder til anvendelse | |
| DK3218358T3 (da) | Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner | |
| DK3368655T3 (da) | Forbedret proteinekspression og fremgangsmåder dertil | |
| DK3077467T3 (da) | Sikkativsammensætning og anvendelse deraf | |
| DK3102200T3 (da) | Terapeutisk forbindelse og sammensætning | |
| DK3498292T3 (da) | Uspa2-proteinkonstruktioner og anvendelser deraf | |
| DK3220750T3 (da) | Oral rehydreringssammensætning og fremgangsmåder dertil | |
| HRP20182134T1 (hr) | Triazinski spoj i njegova upotreba u medicinske svrhe | |
| DK3240436T3 (da) | Sammensætning indeholdende kitin og fordøjelige proteiner | |
| DK3011041T3 (da) | Biodieselsammensætning og dermed forbundet fremgangsmåde og produkter |